GVO Asset Management’s DexCom DXCM Stock Holding History

GVO Asset Management’s Portfolio DXCM Stock Details DXCM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-880	Closed	-$94K	–	25
2021 Q2	$94K	Buy	880 +344	+64%	+$33K	0.08%	52
2021 Q1	$48K	Buy	+536	New	+$50.3K	0.05%	63

Other funds holding DXCM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

GVO Asset Management's DXCM Position: Q3 2021 in Review

GVO Asset Management sold out of DexCom (DXCM) in Q3 2021, closing a stake of 880 shares — an estimated $94K sold.

GVO Asset Management first reported a position in DXCM in Q1 2021 and held it in 2 quarters. The position peaked at $94K in Q2 2021. 795 funds tracked by Wall St. Rank hold DXCM as of Q3 2021.

GVO Asset Management reported no remaining DexCom position as of Q3 2021 after selling out during the quarter.
GVO Asset Management sold 880 DexCom shares in Q3 2021, an estimated $94K.
GVO Asset Management first reported a position in DexCom in Q1 2021 and held it in 2 quarters.
GVO Asset Management's DexCom position peaked at $94K in Q2 2021.
795 funds tracked by Wall St. Rank held DexCom as of Q3 2021.

Based on GVO Asset Management's 13F filing for Q3 2021, filed 20 Oct 2021.